Lexicon Pharmaceuticals, Inc. (LXRX)
Lexicon Pharmaceuticals is a biopharmaceutical company. Co. discovers the functions and pharmaceutical utility of genes and uses those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease. Co. is also developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes. Co. is developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain. In addition, Co. is conducting preclinical research and development and preparing to conduct clinical development of compounds from several additional drug programs.
LXRX SEC Filing Email Alerts Service
Company Name: |
Lexicon Pharmaceuticals, Inc. |
Website: |
www.lexpharma.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding LXRX: |
18 |
Total Market Value Held by ETFs: |
$22.54M |
Total Market Capitalization: |
$539.00M |
% of Market Cap. Held by ETFs: |
4.18% |
|
|
March 29, 2024 10:43 AM Eastern
![](https://www.theonlineinvestor.com/tpixel.gif)
![](https://www.theonlineinvestor.com/tpixel.gif) Buy (3.00 out of 4)
27th percentile
![](https://www.theonlineinvestor.com/tpixel.gif) |
|